Stock Ratings / Health Care / AZTR / financials

TRAW (38) IMNN (42) NCNA (56) XTLB (47) ⌘ Pro Terminal →

Azitra Inc (AZTR) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$0.76 -16.31% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.74

Azitra Inc (AZTR) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $4.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.74 (-3.13%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-7.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AZTR)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (41/100 Composite)

🔍 WHY AZTR SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+11/20 pts (27% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.30-44.6% Next Q

Q2 (-2Q)

Grade D$0.72+0% Next Q

Q3 (-1Q)

Grade D$0.72+5.6% Next Q

Current

Grade D-$0.76-7.2% Hist 90D α

Trajectory: D (49) → D- (41)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AZTR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AZTR currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.38) and Max Pain ($0.80) forces dealer call-delta covering toward $5.59.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AZTR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “AZTR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 41%NO 59%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How AZTR Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $686.0K

FY24

Rev $7.5K

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-0.3%	-$11.0M	-$11.2M	-45%
FY 2024	$7.5K	52%	-80%	-$9.0M	-$10.2M	-45%
FY 2023	$686.0K	52%	-80%	-$11.3M	-$7.4M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AZTR)

✓Walkthrough of AZTR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

AZTR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -69.11%📐 HORIZONTAL RANGE

2026-10-30O $0.71H $0.79L $0.65C $0.76VOL 783.0K

RES: $2.15SUP: $0.38SMA50: $1.38SMA200: $1.83

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AZTR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AZTR Butterfly Map → + Track AZTR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AZTR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AZTR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for AZTR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AZTR)

Health Care Rank #625 of 1016 ⚔️ TRAW vs AZTR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AZTR vs. TRAW, IMNN, NCNA, XTLB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Azitra Inc (AZTR) ranks #625 by composite RQD confidence (41/100, grade D-) and #954 by equity capitalization ($4.6M). Within this direct 5-issuer industry benchmark cohort, AZTR leads on earnings valuation at N/A trailing P/E, while AZTR leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. NCNA currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with AZTR at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
AZTR ACTIVE Azitra Inc	D-	41/100	—	—	-35.0%	-16.31%	$4.6M	Benchmark Subject
TRAW Traws Pharma Inc.	D-	38/100	—	—	-35.0%	-16.34%	$4.6M	/traw-vs-aztr →
IMNN Imunon Inc.	D-	42/100	—	—	-35.0%	+0.35%	$4.7M	/imnn-vs-aztr →
NCNA NuCana plc	D+	56/100	—	—	—	-3.26%	$4.3M	/ncna-vs-aztr →
XTLB XTL Biopharmaceuticals Ltd.	D	47/100	—	—	—	-12.44%	$4.3M	/xtlb-vs-aztr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001701478

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Azitra Inc (AZTR) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $7.5K , and -100.0% cumulative change since FY2023) , GAAP net income of -$11.0M, operating cash flow of -$11.2M, and free cash flow of -$11.2M (-10.4% YoY). On the balance sheet, AZTR closed FY2025 with $5.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$11.0M	-$11.2M	-$11.2M	$5.0M	—
FY2024 (FY)	2024-12-31	$7.5K	-$9.0M	-$10.2M	-$10.2M	$7.4M	—
FY2023 (FY)	2023-12-31	$686.0K	-$11.3M	-$7.4M	-$7.4M	—	—

3. AZTR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AZTR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Azitra Inc (NYSE: AZTR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $0.76 (-16.31% 1D, market cap $4.6M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, AZTR ranks #625 in composite RQD confidence.

How does AZTR compare to TRAW and IMNN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AZTR carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TRAW (Traws Pharma Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $4.6M) and IMNN (Imunon Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $4.7M). Among the 5-stock peer group, AZTR leads on earnings multiple (N/A) while AZTR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AZTR?

Per AZTR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001701478), Azitra Inc generated $0 in revenue (-100.0% YoY), -$11.0M in net income, and -$11.2M in free cash flow against $5.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AZTR trading relative to its 50-day, 200-day, and 52-week technical levels?

AZTR last traded at $0.76 (-16.31% on volume of 1,128,715 shares), positioning the stock -44.93% below its 50-day simple moving average ($1.38) and -58.47% below its 200-day simple moving average ($1.83). Across its 52-week range of $0.52 to $5.32, AZTR sits at the 5.0% percentile with a 14-day RSI of 40.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.86).

AZTR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Azitra Inc (AZTR)?

In FY 2025 (10-K), AZTR converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: AZTR RQD Cockpit AZTR 12M Forecast AZTR Earnings & Move AZTR Dividends & DRIP AZTR Insiders & 13F AZTR Whale Options AZTR Profit Sankey AZTR News & Why